A Nonlinear Physiologic Pharmacokinetic Model: I. Steady-state

Overview

Journal J Pharmacokinet Biopharm

Specialty Pharmacology

Date 1985 Feb 1

PMID 4020623

Citations 4

Authors

J G Wagner

G J Szpunar

J J FERRY

Affiliations

Soon will be listed here.

Abstract

The two-compartment model of Rowland et al., (2) has been extended by replacing first order elimination with Michaelis-Menten elimination kinetics. All of the equations for steady-state concentrations and clearances for zero order (constant rate) input orally (into compartment #2) and intravenously (into compartment #1) are derived and reported. The steady-state concentration in compartment #1, following intravenous administration, is shown to be a nonlinear function of maximal velocity of metabolism, Vm, the Michaelis constant, Km, and liver blood flow, Q; and, following oral administration is dependent only upon Vm and Km and is independent of Q. However, oral bioavailability is a function of Vm, Km, and Q. The model allows physiologic pharmacokinetic interpretation of both linear and nonlinear data; and, together with simple modification of the model, can explain much observed pharmacokinetic data to date particularly for first-pass drugs. Future articles in the series will be concerned with single doses, evaluation of literature data in terms of the model, application of the theory in toxicology and in clinical pharmacokinetics and therapeutics.

Citing Articles

Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the "altered enzyme hypothesis".

Weber C, Stoeckel K, Lalka D Pharm Res. 1994; 11(3):420-5.

PMID: 8008710 DOI: 10.1023/a:1018921306200.

Identifiability and indistinguishability of nonlinear pharmacokinetic models.

Godfrey K, Chapman M, Vajda S J Pharmacokinet Biopharm. 1994; 22(3):229-51.

PMID: 7884651 DOI: 10.1007/BF02353330.

Effect of protein binding on steady-state equations.

Wagner J J Pharmacokinet Biopharm. 1985; 13(5):559-60.

PMID: 3834070 DOI: 10.1007/BF01059338.

Clinical significance of pharmacokinetic models of hepatic elimination.

Morgan D, Smallwood R Clin Pharmacokinet. 1990; 18(1):61-76.

PMID: 2178850 DOI: 10.2165/00003088-199018010-00004.

References

Perrier D, Gibaldi M . Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther. 1974; 191(1):17-24. View

Bass L . Flow dependence of first-order uptake of substances by heterogeneous perfused organs. J Theor Biol. 1980; 86(2):365-76. DOI: 10.1016/0022-5193(80)90012-0. View

WILKINSON G . Statistical estimations in enzyme kinetics. Biochem J. 1961; 80:324-32. PMC: 1244002. DOI: 10.1042/bj0800324. View

Wagner J . Predictability of verapamil steady-state plasma levels from single-dose data explained. Clin Pharmacol Ther. 1984; 36(1):1-4. DOI: 10.1038/clpt.1984.129. View

Ahmad A, Bennett P, Rowland M . Models of hepatic drug clearance: discrimination between the 'well stirred' and 'parallel-tube' models. J Pharm Pharmacol. 1983; 35(4):219-24. DOI: 10.1111/j.2042-7158.1983.tb02916.x. View

Bass L, Winkler K . A method of determining intrinsic hepatic clearance from the first-pass effect. Clin Exp Pharmacol Physiol. 1980; 7(3):339-43. DOI: 10.1111/j.1440-1681.1980.tb00080.x. View

Bass L . Current models of hepatic elimination. Gastroenterology. 1979; 76(6):1504-5. View

Pang K, GILLETTE J . A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow. J Pharmacokinet Biopharm. 1978; 6(5):355-67. DOI: 10.1007/BF01062719. View

Keiding S, Mengel H, Lund J . Hepatic elimination of femoxetine in pig during intravenous infusion. Acta Pharmacol Toxicol (Copenh). 1983; 52(3):234-7. DOI: 10.1111/j.1600-0773.1983.tb01092.x. View

10.

Freedman S, Richmond D, ASHLEY J, Kelly D . Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther. 1981; 30(5):644-52. DOI: 10.1038/clpt.1981.216. View

11.

Sawchuk R, Rector T . Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy. J Pharmacokinet Biopharm. 1979; 7(6):543-55. DOI: 10.1007/BF01061208. View

12.

Dedrick R, Forrester D . Blood flow limitations in interpreting Michaelis constants for ethanol oxidation in vivo. Biochem Pharmacol. 1973; 22(10):1133-40. DOI: 10.1016/0006-2952(73)90229-3. View

13.

Rowland M . Influence of route of administration on drug availability. J Pharm Sci. 1972; 61(1):70-4. DOI: 10.1002/jps.2600610111. View

14.

Bass L, Ribinson P . Effects of capillary heterogeneity on rates of steady uptake of substances by the intact liver. Microvasc Res. 1981; 22(1):43-57. DOI: 10.1016/0026-2862(81)90110-2. View

15.

Keiding S, Johansen S, Winkler K, Tonnesen K, Tygstrup N . Michaelis-Menten kinetics of galactose elimination by the isolated perfused pig liver. Am J Physiol. 1976; 230(5):1302-13. DOI: 10.1152/ajplegacy.1976.230.5.1302. View

16.

Keiding S, Chiarantini E . Effect of sinusoidal perfusion on galactose elimination kinetics in perfused rat liver. J Pharmacol Exp Ther. 1978; 205(2):465-70. View

17.

Wagner J, Wilkinson P, Sedman A, Kay D, Weidler D . Elimination of alcohol from human blood. J Pharm Sci. 1976; 65(1):152-4. DOI: 10.1002/jps.2600650142. View

18.

Wagner J, Szpunar G, FERRY J . Exact mathematical equivalence of the venous equilibration ("well-stirred") model, the sinusoidal perfusion ("parallel-tube") model, and a specific two-compartment open model. Drug Metab Dispos. 1984; 12(4):385-8. View

19.

Pang K, Rowland M . Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm. 1977; 5(6):655-80. DOI: 10.1007/BF01059689. View

20.

Strong J, Dutcher J, Lee W, Atkinson Jr A . Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J Pharmacokinet Biopharm. 1975; 3(4):223-35. DOI: 10.1007/BF01066919. View